- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Piedmont Lithium: Updated Scoping Study Improves Project Economics
Piedmont Lithium is pleased to report the results of the company’s updated Scoping Study for its vertically-integrated Piedmont Lithium project located within the Carolina Tin-Spodumene Belt in North Carolina, USA.
Piedmont Lithium (ASX:PLL) is pleased to report the results of the company’s updated Scoping Study for its vertically-integrated Piedmont Lithium project located within the Carolina Tin-Spodumene Belt in North Carolina, USA. The project includes a lithium hydroxide chemical plantsupplied with spodumene concentrate from an open pit mine and concentrator.
As quoted in the press release:
Integrated project to produce 22,700 tonnes per year of lithium hydroxide
Initial 13-year mine life with 2 years of spodumene concentrate sales and 11 years of integrated operations
Staged development to minimise up-front capital requirements and equity dilution
- Stage 1 initial capex of US$109mm for the Mine/Concentrator and by-product circuits (excluding contingency)
- Stage 2 capex for Chemical Plant funded largely by internal cash flow
Estimated 1st quartile spodumene concentrate costs of US$193/t and lithium hydroxide costs of US$3,112/t, both net of by-product credits and inclusive of royalties
Conventional technology selection in all project aspects
Steady-state annual EBITDA of US$225-245mm and after-tax cash flow of US$180-190mm
Estimated NPV8% of US$888mm and after-tax IRR of 46% with ~2-year payback
Potential mine and project life extension provide the opportunity for further economic upside
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.